Latest Insider Transactions at Mirati Therapeutics, Inc. (MRTX)
This section provides a real-time view of insider transactions for Mirati Therapeutics, Inc. (MRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mirati Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mirati Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
Boxer Capital, LLC |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,658,104
-100.0%
|
-
|
|
Jan 23
2024
|
Boxer Capital, LLC |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,201,440
-100.0%
|
-
|
|
Jan 23
2024
|
Carol Giltner Gallagher |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,363
-76.3%
|
-
|
|
Jan 23
2024
|
Charles M Baum Founder, President, and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
237,871
-78.01%
|
-
|
|
Jan 23
2024
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
154,996
-73.06%
|
-
|
|
Jan 23
2024
|
Alan B. Sandler Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
79,865
-62.88%
|
-
|
|
Jan 23
2024
|
Maria E Martinez |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,273
-58.12%
|
-
|
|
Jan 23
2024
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,028
-68.23%
|
-
|
|
Jan 23
2024
|
John B Moriarty Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,335
-50.47%
|
-
|
|
Jan 23
2024
|
Aaron Ondrey Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,461
-52.9%
|
-
|
|
Jan 23
2024
|
Faheem Hasnain |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,752
-58.24%
|
-
|
|
Jan 23
2024
|
Craig A Johnson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,273
-58.12%
|
-
|
|
Jan 23
2024
|
Bruce L A Carter |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,273
-58.12%
|
-
|
|
Jan 23
2024
|
Aaron I. Davis |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,325
-72.93%
|
-
|
|
Jan 23
2024
|
Julie M Cherrington |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,252
-69.75%
|
-
|
|
Jan 23
2024
|
Shalini Sharp |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,222
-56.4%
|
-
|
|
Jan 16
2024
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,597
-0.68%
|
$94,223
$59.02 P/Share
|
|
Jan 16
2024
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,597
-0.51%
|
$94,223
$59.02 P/Share
|
|
Jan 08
2024
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,090
-1.73%
|
$121,220
$58.92 P/Share
|
|
Jan 04
2024
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,531
-0.96%
|
$88,798
$58.81 P/Share
|
|
Dec 29
2023
|
Aaron I. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+11.14%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+28.27%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Maria E Martinez |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+28.27%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Carol Giltner Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+32.16%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Julie M Cherrington |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+37.7%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Shalini Sharp |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+29.56%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Bruce L A Carter |
BUY
Grant, award, or other acquisition
|
Direct |
6,808
+28.27%
|
$394,864
$58.75 P/Share
|
|
Dec 29
2023
|
Faheem Hasnain |
BUY
Grant, award, or other acquisition
|
Direct |
9,702
+28.16%
|
$562,716
$58.75 P/Share
|
|
Dec 29
2023
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,021
+12.36%
|
$987,218
$58.75 P/Share
|
|
Dec 29
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,021
+9.69%
|
$987,218
$58.75 P/Share
|
|
Dec 29
2023
|
Alan B. Sandler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,021
+17.67%
|
$987,218
$58.75 P/Share
|
|
Dec 29
2023
|
Aaron Ondrey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,021
+30.14%
|
$987,218
$58.75 P/Share
|
|
Dec 29
2023
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,425
+7.62%
|
$1,184,650
$58.75 P/Share
|
|
Dec 18
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,387
-1.66%
|
$136,059
$57.5 P/Share
|
|
Dec 13
2023
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,220
-2.1%
|
$124,320
$56.67 P/Share
|
|
Sep 08
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,388
-1.63%
|
$83,580
$35.63 P/Share
|
|
Sep 08
2023
|
Aaron Ondrey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,412
+27.27%
|
$294,420
$35.66 P/Share
|
|
Aug 11
2023
|
Boxer Capital, LLC |
BUY
Open market or private purchase
|
Direct |
2,402,880
+27.29%
|
$64,877,760
$27.8 P/Share
|
|
Aug 11
2023
|
Boxer Capital, LLC |
BUY
Open market or private purchase
|
Indirect |
115,066
+16.66%
|
$3,106,782
$27.8 P/Share
|
|
Aug 11
2023
|
Faheem Hasnain |
BUY
Open market or private purchase
|
Indirect |
10,791
+50.0%
|
$291,357
$27.8 P/Share
|
|
Aug 09
2023
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
54,054
+19.21%
|
$1,999,998
$37.0 P/Share
|
|
Aug 09
2023
|
Laurie Stelzer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,297
+17.89%
|
$824,989
$37.0 P/Share
|
|
Aug 09
2023
|
Alan B. Sandler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,297
+26.36%
|
$824,989
$37.0 P/Share
|
|
Aug 09
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,297
+13.22%
|
$824,989
$37.0 P/Share
|
|
Aug 09
2023
|
John B Moriarty Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,297
+23.73%
|
$824,989
$37.0 P/Share
|
|
Aug 09
2023
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,297
+17.39%
|
$824,989
$37.0 P/Share
|
|
Jun 22
2023
|
Carol Giltner Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
7,555
+50.0%
|
-
|
|
Jun 02
2023
|
Laurie Stelzer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,647
-5.49%
|
$171,939
$37.06 P/Share
|
|
May 24
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
619
-0.5%
|
$27,855
$45.29 P/Share
|
|
Jan 20
2023
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+29.81%
|
-
|